Please check entered address and try again or go to homepage This Wednesday at 9pm CET, FC Barcelona take on Club de Fútbol Intercity in the Round of 32 of the Copa del Rey It’s a club they have never played before and that very few fans will be familiar with so here are the essentials on the team from Alicante San Juan de Alicante is a primarily residential municipality on the northern outskirts of the Alicante/Elche metropolitan area The main football club in the community was GCD Sant Joan but in 2017 an investment group took it over and changed its name the club has made quick progress from the local leagues to now play at a higher level than Hércules which has traditionally been the biggest team in Alicante It has also twice attempted to fast track this progress It did this first by proposing a merger with Novelda (and thus taking their place) but the move was impeded by the federation as the two clubs were not geographically close enough And it was then beaten by FC Andorra when bidding to take the place of the defunct Reus Deportivo It’s not the first time Intercity have met a Liga club in the Copa del Rey Intercity are now playing in the third tier of Spanish football, Primera Division RFEF, which is divided into two regionalised leagues. Theirs is the same one as Barça Atlétic. They have been struggling at the higher level and are currently in the relegation zone, seven points below the FC Barcelona reserves, with whom they drew 0-0 earlier this season They reached the last 32 of the Copa del Rey thanks to a 2-0 defeat of second division Mirandés Although they usually play at the 2,500 capacity Estadio Antonio Solana due to the huge crowd expected for this game it has been moved to the 29,500 capacity Estadio José Rico Pérez This ground hosted two of Argentina’s games in the 1982 World Cup Intercity has two players that have won full international caps who played 142 games for Mallorca and also had a spell in England with Middlesbrough and then Birmingham City has represented his father’s home nation of Equatorial Guinea 32 times There are also a surprising number of players in the team that have spent time at FC Barcelona in the past Striker Benja played 64 times for Barça B between 2008 and 2011 around the same time that winger Pol Roigé was playing youth football at La Masia winger Carlos Carmona played for two years in the blaugrana reserves before departing for Sporting Gijón And midfielder Xemi Fernández (below) joined Barça B in 2016 before going to Oxford United right back Guillem Jaime (below) grew up at La Masia and played 22 games for the Barça reserves last season and Cameroon-born midfielder Frank Angong was on the Barça B books for the last two seasons With Oriol Soldevila and Cristian Herrera also having a Barça past that's no fewer than eight such players in the current squad Gustavo Siviero played his football at the highest level in Argentina and then came to Spain where he was in the Mallorca side that beat Barça in the 1998 Spanish Super Cup hitting Alicante for the first time in 2017 at Hércules’ manager Sign up for the Spanish News Today Editors Roundup Weekly Bulletin and get an email with all the week’s news straight to your inbox (List price   3  months 12 Bulletins)  and thank you for choosing CamposolToday.com to publicise your organisation’s info or event Camposol Today is a website set up by Murcia Today specifically for residents of the urbanisation in Southwest Murcia providing news and information on what’s happening in the local area which is the largest English-speaking expat area in the Region of Murcia When submitting text to be included on Camposol Today please abide by the following guidelines so we can upload your article as swiftly as possible: Send an email to editor@camposoltoday.com or contact@murciatoday.com Attach the information in a Word Document or Google Doc Also attach a photo to illustrate your article Connecting decision makers to a dynamic network of information Bloomberg quickly and accurately delivers business and financial information Jose Garcia of CF Intercity competes for the ball with Raul Garcia of Athletic Club de Bilbao in Elche 2021 at 4:52 AM EDTBookmarkSaveLock This article is for subscribers only.A sporting minnow poised to become Spain’s first listed soccer club may blaze a trail for bigger teams to follow suit according to a fund manager investing in much bigger European clubs Last month, shareholders of CF Intercity backed plans to list the Spanish fourth-division team based in Sant Joan d’Alacant was killed in a training accident on Thursday The incident happened while the military man was cleaning a submachine gun after completing an exercise at the Rabasa barracks in Alicante As news outlet TodoAlicante reported the Guardia Civil received an alert at 1.21pm Medical services sent to the Alférez Rojas Navarrete complex were unable to save the young man Roldán joined the army in May 2018 at the Nº1 Training Centre in Cáceres Since April 2021 he had been assigned to the Special Operations Group Valencia III of the Special Operations Command A statement said the army's priority is focused on caring for the family and colleagues of the deceased at this time This is the fifth fatal accident in the last five years suffered by this elite unit of the army Eduardo García Molinero lost his life after being hit by an armoured vehicle a 33-year-old female soldier from Extremadura died during a training exercise in Santa Pola In October 2022 Gavalda Macías died when a vehicle overturned died from a gunshot wound during shooting practice in Agost Comentar es una ventaja exclusiva para registrados Metrics details the COVID-19 pandemic followed a two-wave pattern in most countries Hospital admission for COVID-19 in one wave or another could have affected mortality The objective of this study was to evaluate whether the admission of older patients during the different waves before SARS-CoV-2 vaccination was available We compared the mortality rates of patients hospitalized during 2020 before (first wave) and after (second wave) July 7 retrospective cohort of patients admitted to 126 Spanish hospitals for COVID-19 A multivariate logistic regression analysis was performed to control for changes in either the patient or disease profile 22,494 patients had been included (17,784 from the first wave and 4710 from the second one) Overall mortality was 20.4% in the first wave and 17.2% in the second wave (risk difference (RD) − 3.2%; 95% confidence interval (95% CI) − 4.4 to − 2.0) Only patients aged 70 and older (10,973 patients: 8571 in the first wave and 2386 in the second wave) had a significant reduction in mortality (RD − 7.6%; 95% CI − 9.7 to − 5.5) (unadjusted relative risk reduction: 21.6%) variables related to the severity of the disease admission during the second wave remained a protective factor patients aged 70 years and older admitted during the second wave of the COVID-19 pandemic had a significantly lower risk of mortality except in severely dependent persons in need of corticosteroid treatment This effect is independent of patient characteristics This suggests a protective effect of a better standard of care or a lesser degree of healthcare system overload most countries experienced at least two waves of the pandemic after controlling for known mortality factors there was still a lower mortality rate in the second wave we hypothesized that hospital admission in the different waves could affect the mortality of patients with COVID-19 The primary aim of the study was to evaluate whether the admission of older patients during the different waves of 2020 was associated with a different mortality rate and whether this could be explained by differences in the characteristics of either the patients or the severity of the disease Case Fatality Rate (CFR) according to age in patients hospitalized during the first and second waves of COVID-19 expressed as percentage (deceased patients/total patients) The diamonds indicate the point estimate of the risk difference and the horizontal bars represent its 95% confidence interval The differences in baseline characteristics (demographics and comorbidities), clinical presentation upon admission, and treatments received between waves were analyzed (Table 1) There were some differences in demographics in second-wave patients including older age (second wave: 82.0 vs first wave: 80.8 years) a greater proportion of women (second wave: 48.2% vs first wave: 45.2%) a higher proportion of patients with hypertension (second wave: 73.7% vs first wave: 71.3%) and diabetes (second wave: 30.9% vs first wave: 26.3%) and a slightly higher degree of comorbidity (Charlson Comorbidity Index in the second wave: 5.7 vs first wave: 5.4) The clinical manifestations were also slightly different Laboratory results showed some differences: blood glucose and creatinine values were higher in patients admitted in the second wave whereas hemoglobin was lower A high-risk inflammatory pattern was more frequent in the first wave there was greater use of corticosteroids (79.3% vs 39.5%) and remdesivir (12.6% vs 0.4%) Some of these aforementioned variations could be considered protective (e.g. a lower-risk inflammatory pattern) whereas others (higher age higher creatinine levels) would suggest higher risk of mortality A univariate analysis of mortality was performed. Almost all variables were statistically associated with mortality, denoting the large sample size. Table 2 shows data on demographics Although some of the associations were strong The variables and interactions included in the maximal logistic regression model estimated are shown in Table 3 The odds ratios and risk ratios of mortality of being admitted in the second wave versus the first one for the four different combinations of interaction covariates values are shown in Table 4 The protective effect of being admitted during the second wave of COVID-19 is highest for patients without severe dependence who are not treated with corticosteroids and it diminishes when either of these circumstances is present This study confirms a difference in mortality in patients hospitalized for COVID-19 in Spain between the first and the second wave of the pandemic The lower mortality rate observed in the second wave is due to the lower mortality in patients ≥ 70 years; no differences in mortality were observed among younger subjects this is a novel finding that has not been previously described This reduced mortality rate found in older patients hospitalized during the second wave of the COVID-19 pandemic compared to the first wave could be due to some unmeasured or unknown confounders which may be broadly grouped into three categories: differences in the patients or differences in treatment and overall management the lower mortality in the second wave was unchanged after adjusting for the use of these therapies Our results suggest that there may be some factor (or, more probably, combination of factors), associated with hospitalization that influences mortality and changed between the waves. Some potential candidates are changes in the overall management of patients, improvements in clinical expertise, and a lesser degree of hospital overload (Fig. 2). differences in COVID-19 severity and management could confound the estimation of mortality between waves differences in the outcome could be explained by unmeasured patient characteristics and COVID-19 severity factors the analysis of the interactions between severe dependency and systemic corticosteroid treatment with the hospital admission wave has allowed us to discover that the protective effect of the second wave on mortality is highest when both factors are absent somewhat reduced when either of them is present that explain an average protective effect of the second wave may not succeed in improving the prognosis of the most fragile and severe patients such as those requiring corticosteroid treatment We have learned that there are a lot of “intangibles” that influence the prognosis of COVID-19 hospitalization Quick identification of respiratory failure and more have become the new standard of care and are potential uncontrolled factors that could explain the better prognosis in the second wave Most of these factors will have a greater impact on the older people as they are frailer and thus prone to physical deconditioning paralyzing non-emergency surgical procedures leading to a smaller impact on hospital occupancy and healthcare activity It may well be that the lower mortality in the second wave is mainly a reflection of less healthcare system overload As our study does not include data on the true workload borne by the hospitals healthcare system overload leads to shortages which can also have a greater effect on the older persons due to implementation of triage criteria If it were confirmed that healthcare system overload causes greater mortality in the older persons it would be a moral imperative for us as a society to quickly adopt robust preventative measures as soon as another wave is upon us and there is risk of healthcare system overload Our registry cannot answer this crucial question as we lack data on hospital or ICU patient loads at the time of the patients’ admissions In terms of limitations regarding treatment-related variables the effect of remdesivir and tocilizumab on mortality are strongly time-dependent with a narrow window of opportunity and both tocilizumab and corticosteroids are indicated for a worsening respiratory or inflammatory condition Our registry includes data on the timing of the drug initiation but does not include clinical and laboratory findings at that moment so it is not possible to evaluate the exact effect of the drugs The deleterious effect of corticosteroids or tocilizumab in our multivariate analysis should be interpreted as a marker of the patient’s worsening condition The strengths of this study include its multicenter nationwide design as well as the large number of patients included The consecutive inclusion of patients in each center limits selection bias mortality in the older patients hospitalized in Spain with COVID-19 has been significantly lower in the second wave even after adjusting for baseline clinical condition and pharmacological treatment with proven benefits in treating COVID-19 Our results suggest that this reduction of mortality could be related to a better standard of care though other unknown confounding factors cannot be ruled out This is a retrospective cohort study comparing the first and second waves of the COVID-19 epidemic in Spain The first wave was defined as the period between January 1 and July 7 The second wave was defined as the period between July 8 The final weeks of the first wave and the initial weeks of the second one thus defined periods with a low incidence of COVID-19 and few hospital admissions this cut-off point reflects the transition from the greater healthcare system overload which occurred in the initial months to the lesser healthcare system overload of the later months Inclusion criteria for the registry were age ≥ 18 years and first hospital discharge with a confirmed diagnosis of COVID-19 Exclusion criteria were subsequent admissions of the same patient and denial or withdrawal of informed consent Consecutive patients who required hospital admission and who had SARS-CoV-2 infection confirmed by a positive result on real-time polymerase chain reaction (RT-PCR) testing of a nasopharyngeal or sputum sample and who provided verbal consent were included in the registry the inclusion criteria were expanded with two modifications: antigen testing was accepted as a method for confirming diagnosis and reinfections (> 3 months from the initial infection) of the same patient were accepted for inclusion a total of 22,494 patients from 126 hospitals throughout the country were included in the registry Patients were treated at their attending physician’s discretion according to local protocols and clinical judgment Patients included in open-label clinical trials could be included in the registry provided that all information about treatment was available the registry caused no inconvenience to the patients included Clinical investigators all over the country collected data from medical records using a standardized online data capture system (DCS) The DCS includes both a database manager and the set of procedures for the verification of data Patient identifiable data are dissociated and pseudonymized using an alphanumeric sequence and each researcher keeps a protected registry (patient log) for the purpose of data verification and quality control The database platform is hosted in a secure server and both the database and each client–server transfer are encrypted The pseudonymization system allows for safeguarding patient privacy while also complying with ethical considerations and data protection regulations The low-risk category was defined as lactate dehydrogenase (LDH) and D-dimer (DD) values in the first tercile and lymphocyte count in the third tercile The high-risk category was defined as any LDH or DD values in the third tercile or lymphocyte count in the first tercile The moderate-risk category was defined as patients who did not meet the criteria of the low- or high-risk categories Continuous variables were expressed as mean and standard deviation or median and interquartile range (IQR) according to distribution assessed by the Shapiro–Wilk test and standardized normal probability plots Categorical variables were expressed as frequencies and percentages Differences between groups were compared using Student’s t-test or the Mann–Whitney U test for continuous variables and the likelihood-ratio chi-square test for categorical variables A univariate analysis was performed to explore possible risk factors for all-cause death during admission or the next 30 days from discharge and variables associated with the exposure (pandemic wave) using binomial logistic regressions The variables were chosen from an array of clinical and laboratory findings and treatments received according to local protocols almost all variables showed significant differences in the comparisons between exposure and outcome groups in the univariate analysis We created a logistic regression model to assess the effect of being admitted during the first or second wave on all-cause mortality risk We selected a series of predictors associated with the exposure (pandemic wave) and the outcome (mortality) as potential confounding factors The selection criteria also took theoretical arguments or findings from other studies into consideration in order to adjust for factors that could explain a potential difference in the risk of death between the two waves The admitting variables that were ultimately included as possible confounders of the wave effect were age (categorized into decades from 70 years) age-adjusted Charlson Comorbidity Index (reference: moderate comorbidity) degree of dependence (reference: none or mild dependence) arterial stiffness (pulse pressure ≥ 60 mmHg) risk category based on the pattern of inflammation and bilateral pneumonia as well as tocilizumab or corticosteroid therapy during hospitalization first-order interactions between the waves and all potential confounding factors were included in the initial model Multicollinearity was detected for several terms of interaction A chunk test for the rest of interaction terms did show statistical significance (p < 0.001) so individual likelihood ratio tests were performed for every one of them Three interactions with the variable "Wave" remained statistically significant: severe dependency In order to achieve an interpretable estimation and reduce the number of combinations for which to calculate the wave effect on mortality we decided to omit the interaction of the wave with ventilatory support the final logistic regression model included all the confusion terms and the interactions of Wave with Severe dependence and Systemic corticosteroid therapy We did not conduct variable selection once the model was estimated as this maximal model is the best fit for calculating the wave's effect on mortality Adjusted odds ratios and risk ratios were estimated for each combination of the values of interaction terms Adjusted risk ratios were calculated with delta-method standard errors for the wave covariate All analyses were conducted using Stata version 18.0 (StataCorp The SEMI-COVID-19 Registry was approved by the Provincial Research Ethics Committee of Málaga (Spain) on March 27 2020 (Ethics Committee code: SEMI-COVID-19 27/03/20) All experimental protocols were approved by Ethic Committee of Infanta Cristina University Hospital Ethic Committee of Gregorio Marañón University Hospital Ethic Committee of Complejo Hospitalario Universitario de Albacete Ethic Committee of Hospital Universitario La Paz Ethic Committee of Hospital Royo Villanova Ethic Committee of Complejo Hospitalario Universitario de Santiago Ethic Committee of Hospital Universitario Puerta de Hierro Ethic Committee of Hospital Universitario Doctor Peset Ethic Committee of Hospital Clínico San Carlos Ethic Committee of Complejo Asistencial de Segovia Ethic Committee of Complejo Hospital Universitario de Badajoz Ethic Committee of Hospital Universitario Miguel Servet Ethic Committee of Hospital Universitario de la Princesa Ethic Committee of Hospital Universitario Infanta Sofía Ethic Committee of Complexo Hospitalario Universitario A Coruña Ethic Committee of Hospital de Sant Joan Despí Moisès Broggi and Ethic Committee of 12 de Octubre University Hospital The processing of personal data strictly complied with Spanish Law 14/2007 on Biomedical Research; Regulation (EU) 2016/679 of the European Parliament on the protection of natural persons with regard to the processing of personal data and on the free movement of such data and repealing Directive 95/46/EC (General Data Protection Regulation); and Spanish Organic Law 3/2018 on the Protection of Personal Data and the Guarantee of Digital Rights In the periods of maximum hospital care pressure with high number of cases admitted a written informed consent was not possible to obtain if overwork left no time to explain informed consent prepared the written documentation and keep safe it for overwork (March to April 2020 it was noted noted on the medical record that a written informed consent was not possible to obtain as such procedure was approved by the ethics committees The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3 (2020) Docherty, A. B. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ 369, m1985. https://doi.org/10.1136/bmj.m1985 (2020) Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323(20), 2052–2059. https://doi.org/10.1001/jama.2020.6775 (2020) Borobia, A. M. et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J. Clin. Med. https://doi.org/10.3390/jcm9061733 (2020) Casas-Rojo, J. M. et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. Rev. Clin. Esp. 220(8), 480–494. https://doi.org/10.1016/j.rceng.2020.07.003 (2020) Ramos-Rincon, J.-M. et al. Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain. J. Gerontol. A Biol. Sci. Med. Sci. 76(3), e28–e37. https://doi.org/10.1093/gerona/glaa243 (2020) Finelli, L. et al. Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020. JAMA Netw. Open. 4(4), e216556. https://doi.org/10.1001/jamanetworkopen.2021.6556 (2021) Asch, D. A. et al. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic. JAMA Intern. Med. 181(4), 471–478. https://doi.org/10.1001/jamainternmed.2020.8193 (2021) Vahidy, F. S. et al. Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the Houston metropolitan area. JAMA 324(10), 998–1000. https://doi.org/10.1001/jama.2020.15301 (2020) Fan, G. et al. Decreased Case fatality rate of COVID-19 in the second wave: A study in 53 countries or regions. Transbound Emerg. Dis. https://doi.org/10.1111/tbed.13819 (2020) James, N., Menzies, M. & Radchenko, P. COVID-19 second wave mortality in Europe and the United States. Chaos 31(3), 031105. https://doi.org/10.1063/5.0041569 (2021) Nørgaard, S. K. et al. Real-time monitoring shows substantial excess all-cause mortality during second wave of COVID-19 in Europe, October to December 2020. Euro Surveill. https://doi.org/10.2807/1560-7917.ES.2021.26.1.2002023 (2021) Radovanovic, D. et al. Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: An observational prospective study. Respir Med. 178, 106323. https://doi.org/10.1016/j.rmed.2021.106323 (2021) Borghesi, A. et al. Lombardy, Northern Italy: COVID-19 second wave less severe and deadly than the first? A preliminary investigation. Infect. Dis. 53(5), 370–375. https://doi.org/10.1080/23744235.2021.1884745 (2021) Salyer, S. J. et al. The first and second waves of the COVID-19 pandemic in Africa: A cross-sectional study. Lancet 397(10281), 1265–1275. https://doi.org/10.1016/S0140-6736(21)00632-2 (2021) de Souza, F. S. H., Hojo-Souza, N. S., da Silva, C. M. & Guidoni, D. L. Second wave of COVID-19 in Brazil: Younger at higher risk. Eur. J. Epidemiol. 36(4), 441–443. https://doi.org/10.1007/s10654-021-00750-8 (2021) Iftimie, S. et al. First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain. PLoS ONE 16(3), e0248029. https://doi.org/10.1371/journal.pone.0248029 (2021) Hewitt, J. et al. The effect of frailty on survival in patients with COVID-19 (COPE): A multicentre, European, observational cohort study. Lancet Public Health. 5(8), e444–e451. https://doi.org/10.1016/S2468-2667(20)30146-8 (2020) RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384(8), 693–704. https://doi.org/10.1056/NEJMoa2021436 (2021) REMAP-CAP Investigators et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384(16), 1491–1502. https://doi.org/10.1056/NEJMoa2100433 (2021) RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 397(10285), 1637–1645. https://doi.org/10.1016/S0140-6736(21)00676-0 (2021) Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—final report. N. Engl. J. Med. 383(19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764 (2020) Soria, A. et al. The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19. PLoS ONE 16(1), e0246170. https://doi.org/10.1371/journal.pone.0246170 (2021) Ji, Y., Ma, Z., Peppelenbosch, M. P. & Pan, Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob. Health. 8(4), e480. https://doi.org/10.1016/S2214-109X(20)30068-1 (2020) Condes, E. & Arribas, J. R. Impact of COVID-19 on Madrid hospital system. Enferm Infecc. Microbiol. Clin. 39(5), 256–257. https://doi.org/10.1016/j.eimc.2020.06.005 (2021) Rodilla, E. et al. Impact of arterial stiffness on all-cause mortality in patients hospitalized with COVID-19 in Spain. Hypertension 77(3), 856–867. https://doi.org/10.1161/HYPERTENSIONAHA.120.16563 (2020) Carrasco-Sánchez, F. J. et al. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: Data from the Spanish SEMI-COVID-19 Registry. Ann. Med. 53(1), 103–116. https://doi.org/10.1080/07853890.2020.1836566 (2021) Rubio-Rivas, M. et al. Risk categories in COVID-19 based on degrees of inflammation: Data on More than 17,000 patients from the Spanish SEMI-COVID-19 Registry. J. Clin. Med. 10(10), 2214. https://doi.org/10.3390/jcm10102214 (2021) von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 370(9596), 1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X (2007) Download references We gratefully acknowledge all the investigators who participate in the SEMI-COVID-19 Registry (A complete list of the SEMI-COVID-19 Network members is provided at the end of the paper) These authors contributed equally: José-Manuel Casas-Rojo and Juan-Miguel Antón-Santos A list of authors and their affiliations appears at the end of the paper Juan Vicente de la Sota & Javier Villanueva-Martínez Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA) Gracia Villarreal & María Zurita Etayo Biomedical Research Institute of Málaga (IBIMA) José-Manuel Ramos-Rincón & José-Manuel Ramos-Rincón Jose María Mora-Luján & Manuel Rubio-Rivas Victoria Nuñez Rodriguez & Julián Olalla Sierra María Luisa Taboada Martínez & Lara María Tamargo Chamorro Complejo Hospitalario Universitario de Albacete Jose Luis Beato Pérez & Maria Lourdes Sáez Méndez Marta Varas Mayoral & Julia Vásquez Manau Raul Martínez Murgui & Marta Teresa Matía Sanz Maimonides Biomedical Research Institute of Córdoba (IMIBIC) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Juan Luis Romero Cabrera & José David Torres-Peña Complejo Hospitalario Universitario de Santiago María Pazo Nuñez & Paula Maria Pesqueira Fontan Hospital Universitario Puerta de Hierro Majadahonda Jose Manuel Vázquez Comendador & Juan Antonio Vargas Núñez Adela Maria Pina Belmonte & Alba Viana García Andrea María Vellisca González & Miguel Villar Martínez Eva María Ferreira Pasos & Alba Varela García Complejo Hospital Universitario de Badajoz Francisco Javier Monreal Periáñez & Maria Josefa Pascual Perez Jesús Javier González Igual & Rosa García Fenoll Macarena Vargas Tirado & Almudena Villa Marti Inés Suárez García & Llanos Soler Rangel Complexo Hospitalario Universitario A Coruña Francisco Javier Sanmartín Pensado & David Vieito Porto Nicolas Rhyman & Nuria Vázquez Piqueras Azucena Sempere Mira & Philip Wikman-Jorgensen Marcos Sánchez Fernández & Javier Tejada Montes Nuria Ramírez Perea & Andrea Torregrosa García Marina Prieto Dehesa & Pablo Sanz Espinosa Cristina Salazar Mosteiro & Andrea Silva Asiain Mª Soledad Azcona Losada & Beatriz Ruiz Estévez Jesús Vázquez Clemente & Carmen Yera Bergua Andrés de la Peña Fernández & Almudena Hernández Milián Ainara Coduras Erdozain & Ane Labirua-Iturburu Ruiz Alvaro Sánchez dedel AlcazarRío & Leire Toscano Ruiz Jose Luís Peña Somovilla & Elisa Rabadán Pejenaute Nahum Jacobo Torres Yebes & Vanessa Vento Adrian Viteri-Noël & Svetlana Zhilina Zhilina Maria Sanchez Ledesma & Rosa Juana Tejera Pérez Isabel Jiménez Martínez & Teresa García Delange Lara Rey González & Laura Rodrigo Lara Carlos Puig Navarro & José Antonio Todolí Parra Luis Arribas Pérez & Emilia Martínez Velado Ainhoa Rex Guzmán & Aleix Serrallonga Fustier Manuel Lorenzo López Reboiro & Cristina Sardiña González Jose María Pascual Izuel & Zineb Karroud Zamrani Maria del Carmen Vázquez Friol & Laura Vilariño Maneiro Maria de la Sierra Navas Alcántara & Raimundo Tirado-Miranda Alba Barragán Mateos & Andrés Astur Treceño García Julia Marfil Daza & Marcelino Hayek Peraza Verónica Alfaro Lara & Aurora González Estrada Javier Ena & José Enrique Gómez Segado Virginia Gracia Lorenzo & Raquel Monsalvo Arroyo Marcos Guzmán García & Francisco Javier Vicente Hernández Manuel Martín Regidor & Raquel Rodríguez Díez Iris El Attar Acedo & Carmen Mar Sánchez Cano Virginia Herrero García & Berta Román Bernal Cristina Gabara Xancó & Olga Rodríguez Núñez Anyuli Gracia Gutiérrez & Leticia Esther Royo Trallero Jessica Ramírez Taboada & Mar Rivero Rodríguez Carmen Yllera Gutiérrez & Maria Martinez Sela Julia Lobo García & Antía Pérez Piñeiro Nuria Tornador Gaya & Jorge Usó Blasco Angeles Martinez Pascual & Leyre Jorquer Vidal José Marchena Romero & Anabel Martin-Urda Diez-Canseco Bernardino Soldan Belda & David Vicente Navarro Bethania Pérez Alves & Natalia Vicente López Ana Roda Santacruz & Ana Valverde Muñoz Selene Núñez Gaspar & Antonio González Nieto Raquel Gómez Méndez & Ana Rodríguez Álvarez Paula Ortega Toledo & Esther Martin Ponce Cristina Novoa Fernández & Pablo Tellería Gómez Agnés Rivera Austrui & Alberto Zamora Cervantes Diana Sande Llovo & Maria Begoña Valle Feijoo Manuel Jesus Soriano Pérez & Encarna Sánchez Martín Victoria Marquez Fernandez & Ada Viviana Romero Echevarry Lucia Paz Fajardo & Tomás de Vega Santos and the members of the SEMI-COVID-19 Network Analysis and interpretation of data: J.M.C.R. Critical revision of the manuscript for important intellectual content: J.M.N.C. The authors declare no competing interests Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Download citation DOI: https://doi.org/10.1038/s41598-023-42735-5 Anyone you share the following link with will be able to read this content: a shareable link is not currently available for this article Sign up for the Nature Briefing newsletter — what matters in science